200956-75-8

Upstream product

• 7439-92-1 lead 
• 200956-10-1 (2S,3R)-1-tert-Butoxycarbonyl-3-(3-hydroxypropyn-1-yl)-2-phenylpiperidin-3-ol 
• 191669-62-2 (S)-tert-butyl 3-carbonyl-2-phenylpiperidine-1-carboxylic acid 
• 148701-46-6 cis-(3S)-hydroxy-(2S)-phenylpiperidine 
• 159249-47-5 tert-butyl (2S,3S)-3-hydroxy-2-phenylpiperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 200954-98-9 (3R,5S,6S)-3-(2-benzyloxy-5-(trifluoromethoxy)phenyl)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)azaspiro[4.5]decane 
• 200956-77-0 (5R,6S)-6-phenyl-1-oxa-7-(tert-butoxycarbonyl)azaspiro[4.5]dec-3-ene 

Relevant academic research and scientific papers

Use of NK-1 receptor antagonists for treating major depressive disorders

The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor

Stereocontrolled syntheses of epimeric 3-aryl-6-phenyl-1-oxa-7-azaspiro[4.5]decane NK-1 receptor antagonist precursors

Equation presented Complementary stereoselective syntheses of individual C3 epimers of the NK-1 receptor antagonist precursor 1 have been developed. Both diastereomers were derived from the common intermediate 3; introduction of the 3S stereocenter in 1a

Use of NK-1 receptor antagonists for treating stress disorders

The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant the

USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS

The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-